Additionally, the use of anti-Xa in this study allowed monitoring of UFH infusions that was not impacted by the variables that impact aPTT monitoring, such as liver dysfunction, hypercoagulable states, and abnormal Factor II and VIII concentrations. This evidence concerns the gene TNXA and Decreased liver function.